7,211 results match your criteria Imaging in Non-Small Cell Lung Cancer


Increases in Serial Pretreatment F-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy.

Adv Radiat Oncol 2019 Apr-Jun;4(2):429-437. Epub 2018 Nov 26.

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.

Purpose: Quantitative changes in positron emission tomography with computed tomography imaging metrics over serial scans may be predictive biomarkers. We evaluated the relationship of pretreatment metabolic tumor growth rate (MTGR) and standardized uptake value velocity (SUVV) with disease recurrence or death in patients with early-stage non-small cell lung cancer treated with stereotactic ablative radiation therapy (SABR).

Methods And Materials: Under institutional review board approval, we retrospectively identified patients who underwent positron emission tomography with computed tomography at diagnosis and staging and simulation for SABR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2018.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460103PMC
November 2018

Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging.

Clin Cancer Res 2019 Apr 22. Epub 2019 Apr 22.

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Tumors are continuously evolving biological systems, and medical imaging is uniquely positioned to monitor changes throughout treatment. Although qualitatively tracking lesions over space and time may be trivial, the development of clinically relevant, automated radiomics methods that incorporate serial imaging data is far more challenging. In this study, we evaluated deep learning networks for predicting clinical outcomes through analyzing time series CT images of patients with locally advanced non-small cell lung cancer (NSCLC). Read More

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-2495DOI Listing
April 2019
1 Read

A PET study in healthy subjects of brain exposure of C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer.

J Cereb Blood Flow Metab 2019 Apr 20:271678X19843776. Epub 2019 Apr 20.

1 Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.

Osimertinib is a tyrosine kinase inhibitor (TKI) of the mutated epidermal growth factor receptor (EGFRm) with observed efficacy in patients with brain metastases. Brain exposure and drug distribution in tumor regions are important criteria for evaluation and confirmation of CNS efficacy. The aim of this PET study was therefore to determine brain distribution and exposure of C-labelled osimertinib administered intravenously in subjects with an intact blood-brain barrier. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0271678X19843776DOI Listing
April 2019
1 Read

An exceptional group of non-small cell lung cancer difficult to diagnose: Evaluation of lipid-poor adrenal lesions.

Bosn J Basic Med Sci 2019 Apr 18. Epub 2019 Apr 18.

Nuclear Medicine Department, Firat University Medical Faculty, Elazığ, Turkey.

In some non-small cell lung cancer (NSCLC) patients, lipid-poor adrenal adenomas cannot be adequately differentiated from metastases using imaging methods. Invasive diagnostic procedures also have a low negative predictive value (NPV) in such cases. The current study aims to establish a specific and clinically practical metabolic parameter for lipid-poor adrenal lesions (ALs) in NSCLC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17305/bjbms.2019.3837DOI Listing
April 2019
1 Read

Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.

Eur J Cancer 2019 Apr 13;113:87-95. Epub 2019 Apr 13.

Department of Oncology, University of Oxford, Oxford, United Kingdom; Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. Electronic address:

Background: Pre-clinically, phosphoinositide 3-kinase (PI3K) inhibition radiosensitises tumours by increasing intrinsic radiosensitivity and by reducing tumour hypoxia. We assessed whether buparlisib, a class 1 PI3K inhibitor, can be safely combined with radiotherapy in patients with non-small cell lung carcinoma (NSCLC) and investigated its effect on tumour hypoxia.

Methods: This was a 3 + 3 dose escalation and dose expansion phase I trial in patients with advanced NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.03.015DOI Listing
April 2019
1 Read

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.

J Thorac Imaging 2019 Apr 12. Epub 2019 Apr 12.

Departments of Radiology.

Purpose: Targeted inhibition of anaplastic lymphoma kinase (ALK) has been widely used for the treatment of advanced non-small cell lung cancer (NSCLC) with ALK rearrangements. We performed tumor volume analysis of ALK-rearranged advanced NSCLC treated with crizotinib to identify an early predictive marker for prolonged survival.

Materials And Methods: Cases of 42 patients with ALK-rearranged advanced NSCLC (16 men, 26 women; median age: 55. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RTI.0000000000000413DOI Listing
April 2019
1 Read

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome.

Eur J Radiol Open 2019 29;6:128-131. Epub 2019 Mar 29.

Department of Radiology, Brigham and Women's Hospital, 73 Francis St., Boston, MA, 02115 USA.

Purpose: The presence of interstitial lung abnormality (ILA) at diagnosis of stage IV non-small cell lung cancer (NSCLC) patients has previously shown to be associated with shorter overall survival (OS). The present study aimed to validate the association between ILA and shorter OS in a larger cohort of treatment-naïve stage IV NSCLC patients.

Materials And Methods: This study includes 484 patients (205 men and 279 women) with a pathological diagnosis of stage IV NSCLC with pretreatment baseline CT available for review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejro.2019.03.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444119PMC
March 2019
2 Reads

Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy.

Front Oncol 2019 29;9:199. Epub 2019 Mar 29.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

There is increasing use of immune checkpoint blockade (ICB) across multiple cancer types, including in patients at risk for vertebral metastases and cord compression. These patients are often treated with palliative radiotherapy (PRT); however, data evaluating the combination of PRT and ICB in patients with vertebral metastases is limited. Furthermore, patients with cord compression are generally excluded from prospective clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00199DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450051PMC
March 2019
2 Reads

Application of circulating tumor DNA for dynamic monitoring of advanced non-small cell lung cancer treatment response: An open-label, multicenter, prospective, observational study protocol.

Thorac Cancer 2019 Apr 13. Epub 2019 Apr 13.

Department of Oncology IV, First Hospital of Shijiazhuang, Shijiazhuang, China.

Response Evaluation Criteria in Solid Tumors version 1.1 is currently considered the indicator to assess the curative effect of cancer. However, radiographic measurements often fail to detect tiny lesions or changes in the tumor burden, while tumor biomarkers possess low sensitivity and stability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13031DOI Listing
April 2019
2 Reads

Repeatability of texture features derived from magnetic resonance and computed tomography imaging and use in predictive models for non-small cell lung cancer outcome.

Phys Med Biol 2019 Apr 12. Epub 2019 Apr 12.

Radiation Oncology, Virginia Commonwealth University Health System, Richmond, Virginia, UNITED STATES.

Purpose: To evaluate the repeatability of MRI and CT derived texture features and to investigate the feasibility of use in predictive single and multi-modality models for radiotherapy of non-small cell lung cancer. Methods: Fifty-nine texture features were extracted from unfiltered and wavelet filtered images. Repeatability of test-retest features from helical 4D CT scans, true fast MRI with steady state precession (TRUFISP), and volumetric interpolation breath-hold examination (VIBE) was determined by the concordance correlation coefficient (CCC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1361-6560/ab18d3DOI Listing
April 2019
2 Reads

Vascular white matter lesions negatively correlate with brain metastases in malignant melanoma-Results from a retrospective comparative analysis.

Clin Neurol Neurosurg 2019 May 19;180:117-121. Epub 2019 Mar 19.

Klinik für Radioonkologie und Strahlentherapie, Universitätsklinikum Leipzig, Stephanstraße 9 a, 04103, Leipzig, Germany. Electronic address:

Objectives: Brain metastasis (BM) is a major complication of different cancers. There is increasing evidence for influence of vascular factors on BM in patients with non-small cell lung cancer (NSCLC). It is not known if the same is true for other tumors that might rely on different forms of vasculogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2019.03.016DOI Listing
May 2019
1 Read

Metastatic lung cancer associated with Warthin's tumour.

Niger J Clin Pract 2019 Apr;22(4):585-587

Department of Pulmonary Diseases, Health Sciences University Bursa Yuksek Ihtisas Education and Research Hospital, Bursa, Turkey.

Warthin's tumors which can easily be subjected to misinterpretation are encountered commonly in clinical practice. Warthin's tumors which generally have the localization of parotid gland cauda and have a slow growing characteristic can rarely be seen aside from parotid gland; such as cervical lymph nodes and minor salivary glands. A 56-year-old patient's case that comprised atypical coexistence of Warthin tumor with PET/CT scan positive cervical lymph nodes during the diagnostic examination carried out for a pulmonary mass lesion is presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/njcp.njcp_424_18DOI Listing
April 2019
1 Read

Bowel obstruction caused by colonic metastasis of lung adenocarcinoma: a case report and literature review.

World J Surg Oncol 2019 Apr 8;17(1):63. Epub 2019 Apr 8.

Department of Anatomical and Clinical Pathology, Wesley Medical Center, 550 N. Hillside St, Wichita, KS, 67214, USA.

Introduction: Lung cancer is the most common cause of cancer-related deaths globally. Metastatic disease is often found at the time of initial diagnosis in the majority of lung cancer patients. However, colonic metastases are rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12957-019-1611-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454752PMC
April 2019
1 Read

Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo.

J Exp Clin Cancer Res 2019 Apr 5;38(1):148. Epub 2019 Apr 5.

Department of Clinical Laboratory, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, 519000, China.

Background: Recent Clinical trials of administration of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in combination with standard first-line chemotherapy have failed to improve survival in patients with advanced NSCLC, However, the sequential treatment with EGFR-TKIs and chemotherapy is expected to improve survival of NSCLC. The aim of this study is to test the antiproliferative effect of pemetrexed combined with icotinib in different sequences on non-small cell lung cancer (NSCLC) cell lines to determine the optimal combination schedule, and subsequently elaborated the potential mechanisms.

Methods: Six human lung cancer cell lines with wild-type or mutant EGFR gene were exposed to pemetrexed and icotinib combined in different sequences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1133-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451286PMC
April 2019
1 Read

Targeting the temporal dynamics of hypoxia-induced tumor-secreted factors halts tumor migration.

Cancer Res 2019 Apr 5. Epub 2019 Apr 5.

Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy

Targeting microenvironmental factors that foster migratory cell phenotypes is a promising strategy for halting tumor migration. However, lack of mechanistic understanding of the emergence of migratory phenotypes impedes pharmaceutical drug development. Using our 3D microtumor model with tight control over tumor size, we recapitulated the tumor size-induced hypoxic microenvironment and emergence of migratory phenotypes in microtumors from epithelial breast cells and patient-derived primary metastatic breast cancer cells, mesothelioma cells, and lung cancer xenograft cells (PDX). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-3151DOI Listing
April 2019
3 Reads

The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy.

Int J Cardiovasc Imaging 2019 Apr 2. Epub 2019 Apr 2.

Department of Ultrasound, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 Huaihai Road West, Shanghai, China.

Right ventricular (RV) impairment after cancer therapy-related cardiotoxicity and its prognostic implications in lung cancer have not been examined. The present research sought to evaluate RV structure, function, and mechanics in stage III non-small-cell lung cancer (NSCLC) before and after concurrent chemoradiotherapy (CCRT), and to explore the associations between RV impairments, radiation dose, and all-cause mortality. This prospective investigation included 128 inoperable NSCLC patients who were scheduled to receive CCRT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10554-019-01590-0DOI Listing

Low Dose PET Emulation from Decimated High Statistics: A Clinical Validation Study.

Med Phys 2019 Mar 31. Epub 2019 Mar 31.

Siemens Medical Solutions USA, Inc. Knoxville, TN, USA.

Purpose: The fundamental nature of PET, as an event detection system, provides some flexibility for data handling, including retrospective data manipulation. The reorganization of acquisition data allows the emulation of new scans arising from identical radiotracer spatial distributions, but with different statistical compositions, and is especially useful for evaluating the stability and reproducibility of reconstruction algorithms or when investigating extremely low count conditions. This approach is ubiquitous in the research literature but has only been validated, from the point of view of the noise properties, with numerical simulations and phantom data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mp.13517DOI Listing
March 2019
3 Reads

Impact of inline magnetic fields on dose distributions for VMAT in lung tumor.

Phys Med 2019 Mar 9;59:100-106. Epub 2019 Mar 9.

Department of Health Sciences, Faculty of Life Sciences, Kumamoto University, 4-24-1 Kuhonji, Kumamoto, Japan.

The purpose of this study is to investigate the impact of inline magnetic field on dose distribution for volumetric modulated arc therapy (VMAT) in lung tumors located at the chest wall and mediastinum. Two VMAT plans for a thorax phantom with lung tumors of 1 cm and 2 cm in diameter located at the chest wall were created by a treatment planning system. Next, five clinical VMAT plans for a non-small cell lung cancer (NSCLC) at early stages I and II of 5 cm or less in diameter were also used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmp.2019.03.003DOI Listing
March 2019
1 Read

Very Early Response Evaluation by PET/MR in Patients with Lung Cancer-Timing and Feasibility.

Diagnostics (Basel) 2019 Mar 26;9(1). Epub 2019 Mar 26.

Dept. of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.

With the increasing number of therapy options available for patients with lung cancer, early response evaluation is needed. We performed this pilot study to assess the feasibility of early, repeated Positron emission tomography-magnetic resonance (PET/MR), the impact of timing and the capability for response prediction in lung tumors during chemotherapy. Patients with stage IV non-small cell lung cancer referred for chemotherapy were prospectively recruited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics9010035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468790PMC
March 2019
1 Read

[Application of Metabolic Parameters Measured by ¹⁸F-FDG PET/CT in the Evaluation of the Prognosis of Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi 2019 Mar;22(3):167-172

Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University, Qingdao 266100, China.

Tumor-node-metastasis (TNM) staging system is the most important basis for making therapeutic decisions and predicting prognosis of lung cancer patients. The metabolic parameters including standardized uptake value (SUV), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) measured by ¹⁸F-fluorodeoxyglucose-positron emission tomography (¹⁸F-FDG PET/CT) associate with tumor aggressiveness and can provide additional prognostic information. A new staging methodology combines the conventional cTNM with the metabolic tumor burden quantified from the PET images is a better predictor of overall survival with superior stratifying power may help oncologists to make better treatment plans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3779/j.issn.1009-3419.2019.03.09DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441117PMC
March 2019
2 Reads

Spectral CT and its specific values in the staging of patients with non-small cell lung cancer: technical possibilities and clinical impact.

Clin Radiol 2019 Mar 21. Epub 2019 Mar 21.

Department of Radiology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany; Department of Radiology, University Hospital Munich, Ludwig-Maximilians University (LMU), Munich, Germany. Electronic address:

Aim: To investigate how spectral computed tomography (SCT) values impact the staging of non-small cell lung cancer (NSCLC) patients.

Materials And Methods: One hundred and thirteen patients with confirmed NSCLC were included in a prospective cohort study. All patients underwent single-phase contrast-enhanced SCT (using the fast tube voltage switching technique, 80-140 kV). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.crad.2019.02.010DOI Listing
March 2019
1 Read

Nanomedicine-Assisted Combination Therapy of NSCLC: New Platinum-Based Anticancer Drug Synergizes the Therapeutic Efficacy of Ganetespib.

Nanotheranostics 2019 11;3(1):120-134. Epub 2019 Feb 11.

Department of Chemistry, Pittsburg State University, 1701 S. Broadway Street, Pittsburg, Kansas 66762, United States.

K-RAS is the most common mutated oncogene associated with Non-Small-Cell Lung Cancer (NSCLC). So far, there are no promising chemotherapies for the direct inhibition of K-RAS, and considered to be undruggable. In this work, we have introduced a new platinum-based cyanoximate complex, Pt(MCO) as an anti-cancer drug to enhance the therapeutic efficacy of Hsp90 inhibitor drug, ganetespib for the combination therapy of NSCLC. Read More

View Article

Download full-text PDF

Source
http://www.ntno.org/v03p0120.htm
Publisher Site
http://dx.doi.org/10.7150/ntno.28468DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427934PMC
February 2019
4 Reads

Pre-treatment F-FDG PET-based radiomics predict survival in resected non-small cell lung cancer.

Clin Radiol 2019 Mar 18. Epub 2019 Mar 18.

Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

Aim: To assess the prognostic value of 2-[F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)-based radiomics using a machine learning approach in patients with non-small cell lung cancer (NSCLC).

Materials And Methods: Ninety-three patients with stage I-III NSCLC who underwent combined PET/computed tomography (CT) followed by curative resection. A total of 35 unique quantitative radiomic features was extracted from the PET images, which included imaging phenotypes such as pixel intensity, shape, and texture. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.crad.2019.02.008DOI Listing
March 2019
1 Read

Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers.

Ann Oncol 2019 Mar 21. Epub 2019 Mar 21.

Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Introduction: Immunotherapy is regarded one of the major breakthroughs in cancer treatment. Despite its success, only a subset of patients responds - urging the quest for predictive biomarkers. We hypothesize that Artificial Intelligence (AI) algorithms can automatically quantify radiographic characteristics that are related to and may therefore act as non-invasive radiomic biomarkers for immunotherapy response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz108DOI Listing
March 2019
13 Reads

Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.

Lung Cancer 2019 Apr 19;130:194-200. Epub 2019 Feb 19.

Roche Diagnostics International Ltd, Rotkreuz, Switzerland. Electronic address:

Objectives: The biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymis protein 4 (HE4) are useful in the diagnosis, prognosis, and monitoring of non-small cell lung cancer (NSCLC), but their combination has not been investigated yet. The objective of this analysis was to evaluate the ability of CYFRA 21-1 and HE4 to predict recurrence as part of follow-up monitoring in patients with adenocarcinoma (ADC) of the lung.

Materials And Methods: Serum samples were collected from patients with stage I-IIIA ADC preoperatively and during follow-up at 3, 6, 12, 18, and 24 months and then every 6-12 months up to 5 years post-R0 resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.02.017DOI Listing
April 2019
2 Reads

Probabilistic independent component analysis of dynamic susceptibility contrast perfusion MRI in metastatic brain tumors.

Cancer Imaging 2019 Mar 18;19(1):14. Epub 2019 Mar 18.

UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA.

Purpose: To identify clinically relevant magnetic resonance imaging (MRI) features of different types of metastatic brain lesions, including standard anatomical, diffusion weighted imaging (DWI) and dynamic susceptibility contrast (DSC) perfusion MRI.

Methods: MRI imaging was retrospectively assessed on one hundred and fourteen (N = 114) brain metastases including breast (n = 27), non-small cell lung cancer (NSCLC, n = 43) and 'other' primary tumors (n = 44). Based on 114 patient's MRI scans, a total of 346 individual contrast enhancing tumors were manually segmented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40644-019-0201-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423873PMC
March 2019
2 Reads

Fluorine-18-fluorodeoxyglucose-positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal-related events.

Thorac Cancer 2019 Apr 18;10(4):980-987. Epub 2019 Mar 18.

Positron Imaging Center, Aizawa Hospital, Matsumoto, Japan.

Background: Fluorine-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) uptake in primary lesions has been well studied, but little information is available about metastatic bone lesions in patients with lung cancer. The present study was performed to evaluate the relationships between metastatic bone FDG uptake and clinical parameters in patients with lung cancer.

Methods: FDG uptake was evaluated as the maximum standardized uptake (SUVmax) value of each targeted bone lesion, and the bone to primary lesion ratio of SUVmax (B/P ratio) was calculated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1759-7714.13041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449251PMC

Dynamic Contrast-enhanced Area-detector CT vs Dynamic Contrast-enhanced Perfusion MRI vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy.

Magn Reson Med Sci 2019 Mar 18. Epub 2019 Mar 18.

Division of Functional and Diagnostic Imaging Research, Department of Radiology, Kobe University Graduate School of Medicine.

Purpose: To directly compare the utility for therapeutic outcome prediction of dynamic first-pass contrast-enhanced (CE)-perfusion area-detector computed tomography (ADCT), MR imaging assessed with the same mathematical method and 2-[fluorine-18]-fluoro-2-deoxy-d-glucose-positron emission tomography combined with CT (PET/CT) for non-small cell lung cancer (NSCLC) patients treated with chemoradiotherapy.

Materials And Methods: Forty-three consecutive stage IIIB NSCLC patients, consisting of 25 males (mean age ± standard deviation: 66.6 ± 8. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2463/mrms.mp.2018-0158DOI Listing
March 2019
1 Read

Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.

BMC Cancer 2019 Mar 12;19(1):220. Epub 2019 Mar 12.

Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.

Background: Breast cancer patient-derived xenograft (BC-PDX) models represent a continuous and reproducible source of circulating tumor cells (CTCs) for studying their role in tumor biology and metastasis. We have previously shown the utility of BC-PDX models in the study of CTCs by immunohistochemistry (IHC) on serial paraffin sections and manual microscopic identification of cytokeratin-positive cells, a method that is both low-throughput and labor-intensive. We therefore aimed to identify and characterize CTCs from small volume mouse blood samples and examined its practical workflow in a study of BC-PDX mice treated with chemotherapy using an automated imaging platform, the AccuCyte®-CyteFinder® system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5382-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419430PMC
March 2019
6 Reads

Development of DNA Aptamers to Native EpCAM for Isolation of Lung Circulating Tumor Cells from Human Blood.

Cancers (Basel) 2019 Mar 12;11(3). Epub 2019 Mar 12.

Federal Research Center "Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Science", Krasnoyarsk 660036, Russia.

We selected DNA aptamers to the epithelial cell adhesion molecule (EpCAM) expressed on primary lung cancer cells isolated from the tumors of patients with non-small cell lung cancer using competitive displacement of aptamers from EpCAM by a corresponding antibody. The resulting aptamers clones showed good nanomolar affinity to EpCAM-positive lung cancer cells. Confocal microscopy imaging and spectral profiling of lung cancer tissues confirmed the same protein target for the aptamers and anti-EpCAM antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11030351DOI Listing
March 2019
4 Reads

Association between 18F-FDG uptake in PET/CT, Nrf2, and NQO1 expression and their prognostic significance in non-small cell lung cancer.

Neoplasma 2019 Mar 10;2019. Epub 2019 Mar 10.

Department of Pathology, Ajou University School of Medicine, Ajou University, Suwon, South Korea.

Two pentose phosphate pathway-related proteins, NF-E2-related factor 2 (Nrf2)/ NAD(P)H dehydrogenase (Quinone) 1 (NQO1) regulate the expression of glucose metabolism and antioxidant genes. We evaluated the prognostic significance of NRF2, NQO1 and 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) parameter and their relationship with non-small cell lung cancer (NSCLC) histology. A total of 241 patients, who underwent surgical resection for NSCLC, were reviewed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4149/neo_2018_181007N742DOI Listing
March 2019
1 Read

Rapidly progressive miliary brain metastasis of lung cancer after EGFR tyrosine kinase inhibitor discontinuation: An autopsy report.

Neuropathology 2019 Apr 13;39(2):147-155. Epub 2019 Mar 13.

Department of Pathology, Mitsui Memorial Hospital, Tokyo, Japan.

Miliary brain metastasis is a rare type of brain metastasis, in which carcinoma cells disseminate to numerous foci confined to Virchow-Robin/subpial spaces. Symptoms usually progress within several months, and magnetic resonance imaging (MRI) shows multiple small contrast-enhancing lesions. We report an autopsy case of a patient who rapidly deteriorated within a week due to miliary brain metastasis after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) discontinuation, without contrast-enhancing lesions on MRI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/neup.12542DOI Listing
April 2019
2 Reads

Radiotherapy boost in patients with hypoxic lesions identified by F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up].

Eur J Nucl Med Mol Imaging 2019 Mar 13. Epub 2019 Mar 13.

Department of Nuclear Medicine, Henri Becquerel Cancer Center and Rouen University Hospital, & QuantIF - LITIS [EA (Equipe d'Accueil) 4108 - FR CNRS 3638], Faculty of Medicine, University of Rouen, Rouen, France.

Purpose: Chemoradiotherapy is the reference curative-intent treatment for nonresectable locally advanced non-small-cell lung carcinoma (NSCLC), with unsatisfactory survival, partially due to radiation resistance in hypoxic tissues. The objective was to update survival and toxicity at 3 years following radiotherapy boost to hypoxic tumours in NSCLC patients treated with curative-intent chemoradiotherapy.

Methods: This was an open-label, nonrandomized, multicentre, phase II clinical trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04285-9DOI Listing
March 2019
2 Reads

Nck-associated protein 1 associates with HSP90 to drive metastasis in human non-small-cell lung cancer.

J Exp Clin Cancer Res 2019 Mar 11;38(1):122. Epub 2019 Mar 11.

Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia, Augusta University, 1120 15th Street, Augusta, GA, 30912, USA.

Background: Metastatic lung cancer is a life-threatening condition that develops when cancer in another area of the body metastasizes, or spreads, to the lung. Despite advances in our understanding of primary lung oncogenesis, the biological basis driving the progression from primary to metastatic lung cancer remains poorly characterized.

Methods: Genetic knockdown of the particular genes in cancer cells were achieved by lentiviral-mediated interference. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1124-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417146PMC
March 2019
1 Read

Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses.

Radiat Oncol 2019 Mar 13;14(1):44. Epub 2019 Mar 13.

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong An Road, Shanghai, 200032, China.

Background: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren't yet approved or economically inaccessible. However, the pattern of failure and clinical value of radiotherapy in metastatic crizotinib-treated ALK-mutant lung cancer, with or without baseline brain metastases (BBM), are largely unknown.

Methods: Consecutive crizotinib-treated NSCLC patients with adequate imaging and measurable disease were retrospectively enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13014-019-1240-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417092PMC
March 2019
4 Reads
2.546 Impact Factor

Pattern of recurrence after CyberKnife stereotactic body radiotherapy for peripheral early non-small cell lung cancer.

J Thorac Dis 2019 Jan;11(1):214-221

Department of Radiation Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Hyogo, Japan.

Background: The treatment efficacy after CyberKnife stereotactic body radiotherapy (SBRT) have not been adequately addressed. The purpose of this study was to investigate pattern of recurrence according to irradiation field after CyberKnife SBRT for early-stage non-small cell lung cancer (NSCLC).

Methods: This retrospective study included patients with peripheral cT1/2N0M0 NSCLC that was treated with SBRT using a CyberKnife between May 2013 and March 2016 at single institute and followed up by more than two imaging examinations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.12.115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384354PMC
January 2019
2 Reads

Three-dimensional structure tensor based PET/CT fusion in gradient domain.

Authors:
Yuanjun Wang Yu Liu

J Xray Sci Technol 2019 Mar 2. Epub 2019 Mar 2.

Department of Radiology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.

Gradient based image fusion can more effectively incorporate edge details using structure tensor, which is successfully used in 2D image fusion. In this study, we generalized and applied this gradient based image fusion method into 3D for non-small cell lung cancer PET/CT image fusion. According the characteristic of lung PET/CT images, we proposed a novel 3D structure tensor based feature, which can be used to construct a weighted structure tensor containing important local detail of both PET and CT images. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/XST-180451DOI Listing
March 2019
1 Read

[18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer.

Tomography 2019 Mar;5(1):145-153

Departments of Radiology.

We identified computational imaging features on 18F-fluorodeoxyglucose positron emission tomography (PET) that predict recurrence/progression in non-small cell lung cancer (NSCLC). We retrospectively identified 291 patients with NSCLC from 2 prospectively acquired cohorts (training, n = 145; validation, n = 146). We contoured the metabolic tumor volume (MTV) on all pretreatment PET images and added a 3-dimensional penumbra region that extended outward 1 cm from the tumor surface. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18383/j.tom.2018.00026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403030PMC
March 2019
3 Reads

Prediction of pleural invasion using different imaging tools in non-small cell lung cancer.

Ann Transl Med 2019 Jan;7(2):33

Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

Clinical staging of non-small cell lung cancer (NSCLC) is used for planning therapeutic strategies. In particular, pleural invasion is regarded as an indicator for upstaging to T2 or T3 in the current 8th TNM staging system; patients with pleural invasion should be indicated for lobectomy rather than sublobar resection. Therefore, accurate preoperative prediction of pleural invasion is important for surgical planning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2019.01.15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381262PMC
January 2019
3 Reads

Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.

Curr Oncol 2019 Feb 1;26(1):e57-e63. Epub 2019 Feb 1.

Department of Radiation Oncology and Developmental Therapeutics, BC Cancer-Fraser Valley Centre, Surrey, and Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, BC.

Introduction: Stereotactic ablative radiotherapy (sabr) is a relatively new technique for the curative-intent treatment of patients with inoperable early-stage non-small-cell lung cancer (nsclc). Previous studies have demonstrated a prognostic value for positron emission tomography-computed tomography (pet/ct) parameters, including maximal standardized uptake value (suv), metabolic tumour volume (mtv), and total lesion glycolysis (tlg) in lung cancer patients. We aimed to determine which pet/ct parameter is most prognostic of local control (lc) and overall survival (os) in patients treated with sabr for nsclc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380634PMC
February 2019

Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer.

BMJ Case Rep 2019 Mar 7;12(3). Epub 2019 Mar 7.

Hematology/Oncology, University of Southern California-Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, USA.

We describe the clinical course of a 64-year-old woman with stage IVa lung adenocarcinoma who presented with over 1 month of fatigue, unintentional weight loss and emesis. She initiated treatment with nivolumab immunotherapy 1 year prior and had been tolerating the treatment well. A comprehensive workup revealed multiple endocrinological abnormalities consistent with hypophysitis leading to hypopituitarism in the form of central adrenal insufficiency and hypogonadism as well as a partially empty sella on imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-228135DOI Listing
March 2019
2 Reads

Texture Analysis on [F]FDG PET/CT in Non-Small-Cell Lung Cancer: Correlations Between PET Features, CT Features, and Histological Types.

Mol Imaging Biol 2019 Mar 7. Epub 2019 Mar 7.

Section of Nuclear Medicine and Health Physics, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Piazza Lucio Severi 1, 06132, Perugia, Italy.

Purpose: The study aims to investigate the correlations between positron emission tomography (PET) texture features, X-ray computed tomography (CT) texture features, and histological subtypes in non-small-cell lung cancer evaluated with 2-deoxy-2-[F]fluoro-D-glucose PET/CT.

Procedures: We retrospectively evaluated the baseline PET/CT scans of 81 patients with histologically proven non-small-cell lung cancer. Feature extraction and statistical analysis were carried out on the Matlab platform (MathWorks, Natick, USA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11307-019-01336-3DOI Listing
March 2019
1 Read

Radiotherapy enhances responses of lung cancer to CTLA-4 blockade.

J Immunother Cancer 2019 Mar 6;7(1):64. Epub 2019 Mar 6.

The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.

Formenti et al. have recently reported the clinical outcomes and translational readouts of a trial of the anti-CTLA-4 inhibitor, ipilimumab, in combination with palliative radiotherapy in 39 patients with non-small cell lung cancer. A radiological response was seen in 18% of patients and 31% of patients experienced disease control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0542-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404307PMC
March 2019
1 Read

A 3D quantitative imaging biomarker in pre-treatment MRI predicts overall survival after stereotactic radiation therapy of patients with a singular brain metastasis.

Acta Radiol 2019 Mar 6:284185119831692. Epub 2019 Mar 6.

4 Department of Radiation Oncology, Charité - University Medicine, Berlin, Germany.

Background: Brain metastases (BM) are the most frequent intracranial malignant tumor. Various prognostic factors facilitate the prediction of survival; however, few have become tools for clinical use.

Purpose: To investigate the role of three-dimensional (3D) quantitative tissue enhancement in pre-treatment cranial magnetic resonance imaging (MRI) as a radiomic biomarker for survival (OS) in patients with singular BM treated with stereotactic radiation therapy (SRT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0284185119831692DOI Listing
March 2019
1 Read

Interobserver variability of image-derived arterial blood SUV in whole-body FDG PET.

EJNMMI Res 2019 Mar 4;9(1):23. Epub 2019 Mar 4.

PET Center, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstraße 400, Dresden, Germany.

Background: Today, the standardized uptake value (SUV) is essentially the only means for quantitative evaluation of static [F-]fluorodeoxyglucose (FDG) positron emission tomography (PET) investigations. However, the SUV approach has several well-known shortcomings which adversely affect the reliability of the SUV as a surrogate of the metabolic rate of glucose consumption. The standard uptake ratio (SUR), i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-019-0486-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399366PMC

Incidence and evolution of imaging changes on cone-beam CT during and after radical radiotherapy for non-small cell lung cancer.

Radiother Oncol 2019 Mar 31;132:121-126. Epub 2018 Dec 31.

Department of Radiotherapy, Clatterbridge Cancer Centre NHS Foundation Trust, United Kingdom; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, United Kingdom.

Background And Purpose: Cone beam CT (CBCT) is used to improve accuracy of radical radiotherapy by adjusting treatment to the observed imaging changes. To ensure appropriate adjustment, image interpretation should precede any changes to treatment delivery. This study provides the methodology for image interpretation and the frequency and evolution of the changes in patients undergoing radical radiotherapy for localised and locally advanced non-small cell lung cancer (NSCLC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2018.12.009DOI Listing
March 2019
3 Reads

Investigation of thoracic four-dimensional CT-based dimension reduction technique for extracting the robust radiomic features.

Phys Med 2019 Feb 19;58:141-148. Epub 2019 Feb 19.

Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Robust feature selection in radiomic analysis is often implemented using the RIDER test-retest datasets. However, the CT Protocol between the facility and test-retest datasets are different. Therefore, we investigated possibility to select robust features using thoracic four-dimensional CT (4D-CT) scans that are available from patients receiving radiation therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmp.2019.02.009DOI Listing
February 2019

Centrally-located lung cancer and risk of occult nodal disease: an objective evaluation of multiple definitions of tumor centrality with a dedicated imaging software.

Eur Respir J 2019 Feb 28. Epub 2019 Feb 28.

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Introduction: Current guidelines recommend invasive mediastinal staging in patients with centrally located radiographic stage T1N0M0 non-small cell lung cancer. The lack of a specific definition of central tumor has resulted in discrepancies among guidelines and heterogeneity in practice patterns.

Methods: Our objective was to study specific definitions of tumor centrality and their association with occult nodal disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1183/13993003.02220-2018DOI Listing
February 2019
1 Read

Next-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Leptomeningeal Carcinomatosis: Review of 2 Cases.

Neurologist 2019 Mar;24(2):59-61

Department of Neurology, Mayo Clinic, Scottsdale, AZ.

Introduction: Epidermal growth factor receptor (EGFR) mutation status is strongly correlated with leptomeningeal carcinomatosis in non-small cell lung cancer. Historically, patients were treated with radiotherapy, intrathecal chemotherapy or first-generation EGFR tyrosine kinase inhibitors (TKIs); however, most would eventually develop resistance and disease progression. Therefore, recent interest has sparked in investigating next-generation EGFR-TKI monotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/NRL.0000000000000220DOI Listing
March 2019
4 Reads

Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice.

Transl Oncol 2019 Apr 23;12(4):640-645. Epub 2019 Feb 23.

AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address:

The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2019.01.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393699PMC
April 2019
1 Read